Support
News
Bionote, Listed on KOSPI (Korea Composite Stock Price Index) as of 22nd of December

DISCLAIMER: This news article is a direct translation of the original Korean article from MTN. BioNote Inc. does not claim any right to the article or claim any ownership.

The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.

Bionote, a veterinary diagnostics and biological raw materials company, has been listed on KOSPI, the Korea Composite Stock Price Index, as of 22nd of December.
At the Listing Event held at the Korea Exchange on the 22nd, DVM Byung-Ki Cho (CEO of Bionotoe), Jae-Jun Lim (Head of Korea Exchange Securities Market Division), Young-Chae Jeong (CEO of NH Investments & Securities), Il-Moon Jeong (CEO of Korea Investments & Securities) and Nam-Ki Chae (President of Korea IR Service) was in attendance.

Bionote, founded in 2003, is a affiliate company of SD Biosensor and has become one of the world's leading veterinary diagnostics and biological raw materials company representing Korea, through the accumulation of proprietary R&D and know-how.
Based on the company's unique genetic recombinant antigen/antibody development technical ability and manufacturing technology, it stands out in the immunodiagnostics field. Furthermore, the company can implement all processes from raw material manufacturing to finished product manufacturing through its proprietary technologies.
Bionote's KOSPI listing is expected to be a giant leap towards becoming top 3 in the world in animal diagnostics and biological raw materials field. Increased brand recognition, advantageous positionings in M&A negotiations and recruitment of talented individuals are just some of the advantages of being listed on KOSPI, through which Bionote will continue to accelerate the expansion of the company and its business

Earlier, CEO of Bionote, DVM Byung-Ki Cho, strongly emphasized that he will personally make sure to fulfill Bionote's responsibilities and obligations to its investors as well as share the fruits of corporate growth with its investors.











 

LIST